The Gilead Innovation Chair in Oncology on the Cancer Center at Clínica Universidad de Navarra (Gilead-CCUN) has launched its inaugural awards to honor revolutionary Spanish researchers within the area of Oncology. These awards will acknowledge the highest two articles specializing in innovation in Artificial Intelligence utilized to Oncology, with separate classes for analysis and scientific functions.
Dr. Antonio González, director of the Cancer Center Clínica Universidad de Navarra and Chairman of Gilead-CCUN, emphasised the significance of integrating analysis and care to speed up the interpretation of scientific developments into improved affected person outcomes. Artificial Intelligence has considerably expanded potentialities in Oncology, and the Chair goals to steer in its implementation.
Gemma Palacios, medical director of Oncology at Gilead in Spain, highlighted Gilead’s dedication to innovation and its promotion within the area of oncology. Through the Gilead-CCUN Chair and the inaugural awards, they purpose to strengthen their dedication to science, analysis, and steady training to innovate and supply hope to sufferers for higher high quality of life.
Researchers have till July 27 to submit their proposals, with eligible initiatives being printed or accepted for publication earlier than May 31, 2024. An unbiased panel of specialists will consider the submissions primarily based on methodological high quality, relevance, originality, affect, and scientific contribution. The awards ceremony is scheduled for later in the summertime.
The announcement of the awards came about throughout a press occasion organized by the Chairman on the Universidad de Navarra Clinic in Madrid, which introduced collectively specialists devoted to advancing analysis, skilled improvement, and scientific dissemination for the good thing about sufferers. The occasion additionally addressed the present state of most cancers in Spain and globally, with contributions from numerous key figures within the area, together with medical doctors, executives, and affected person advocates.